Digital biomarkers are defined as objective, quantifiable physiological & behavioral data collected and measured through digital devices such as portables, wearables, implantables, and/or digestible. The data collected by these digital devices is typically used to explain, influence, or predict health-related outcomes. Thus, the demand for digital biomarkers is increasing with a rapid pace.
Market Dynamics:
Growing prevalence of chronic diseases, rising adoption of digital healthcare solutions, increasing research and development, growing adoption of patient-centric healthcare applications, rising use of smartphones, emergence of novel wearables, and expanding therapeutic applications are major factors expected to drive growth of the global digital biomarkers market.
For instance, in February 2023, Ad Scientiam announced the launch of two ambitious programs to develop and validate digital biomarkers for self-assessment of patients suffering from generalized myasthenia gravis (gMG) and neuromyelitis optica spectrum disorders (NMOSD). The programs will leverage assets, methodologies, and expertise built by Ad Scientiam over the past five years and are supported by Alexion, AstraZeneca Rare Disease.
Key features of the study:
- This report provides in-depth analysis of the global digital biomarkers market, and provides market size (US$ Billion) and compound annual growth rate (CAGR%) for the forecast period (2023-2030), considering 2022 as the base year.
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
- It profiles key players in the global digital biomarkers market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
- Key companies covered as a part of this study include AliveCor Inc., Altoida Inc., Amgen Inc., Human API, Fitbit, Inc., Biogen Inc, Bayer AG, Akili Interactive Labs, Evidation Health, Inc., GlaxoSmithKline Plc, and Eli Lilly and Company, among others.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
- The global digital biomarkers market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global digital biomarkers market.
Detailed Segmentation:
- Global Digital Biomarkers Market, By Data Collection Tools:
- Wearable Devices
- Implantable Components/Sensors
- Mobile/Tablet Apps
- Platforms
- Desktop Based Software
- Data Integration (Systems that Integrate Data)
- Global Digital Biomarkers Market, By Application:
- Sleep and Movement
- Cardiovascular Disease
- Mood and Behavior
- Pain Management
- Neurodegenerative Disorders
- Respiratory Conditions
- Global Digital Biomarkers Market, By End User:
- Biopharmaceutical Companies
- Providers
- Payers
- Global Digital Biomarkers Market, By Region:
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East
- Africa
- Company Profiles:
- AliveCor Inc.
- Altoida Inc.
- Amgen Inc.
- Human API
- Fitbit, Inc.
- Biogen Inc.
- Bayer AG
- Akili Interactive Labs
- Evidation Health, Inc.
- GlaxoSmithKline Plc
- Eli Lilly and Company
